Clinical applications of sodium oxybate (GHB): from narcolepsy to alcohol withdrawal syndrome
- PMID: 26698265
Clinical applications of sodium oxybate (GHB): from narcolepsy to alcohol withdrawal syndrome
Abstract
Gamma-hydroxybutyrate (GHB) is a short chain fatty acid endogenously produced within the central nervous system (CNS) and acts as a precursor and metabolite of the inhibitory neurotransmitter γ-aminobutyric acid (GABA). Although, it is an illegal recreational drug of abuse, its sodium salt (sodium oxybate) has been utilized as a medication for a number of medical conditions. The first aim of this review was to focus on current applications of sodium oxybate for the treatment of narcolepsy, with a particular emphasis on the key symptoms of this disorder: cataplexy and excessive daytime sleepiness (EDS). Secondly, the effectiveness of sodium oxybate therapy for the treatment of alcohol withdrawal syndrome (AWS) and the maintenance of alcohol abstinence has been assessed. Nowadays, sodium oxybate is the first-line treatment for narcolepsy and it is highly effective in meliorating sleep architecture, decreasing EDS and the frequency of cataplexy attacks in narcoleptic patients. Sodium oxybate currently finds also application in the treatment of AWS and the maintenance of alcohol abstinence in alcoholics. Most of the studies evaluating the efficacy of GHB in the treatment of AWS use a dosage of 50 mg/kg divided in three or four administrations per day. Human studies showed that GHB (dose of 50 mg/kg, divided in three administrations per day) is capable to increase the number of abstinent days, reduce alcohol craving and decrease the number of drinks per day. However, there is limited randomized evidence and, thus, GHB cannot be reliably compared to clomethiazole or benzodiazepines. Some randomized data suggest that GHB is better than naltrexone and disulfiram regarding abstinence maintenance and prevention of craving in the medium term i.e. 3-12 months. It is recommended that GHB should be used only under strict medical supervision, since concerns about the abuse/misuse of the drug and the addiction potential have been arisen.
Similar articles
-
Sodium Oxybate Therapy for Alcohol Withdrawal Syndrome and Keeping of Alcohol Abstinence.Curr Drug Metab. 2018;19(13):1056-1064. doi: 10.2174/1389200219666171207122227. Curr Drug Metab. 2018. PMID: 29219048 Review.
-
The abrupt cessation of therapeutically administered sodium oxybate (GHB) does not cause withdrawal symptoms.J Toxicol Clin Toxicol. 2003;41(2):131-5. doi: 10.1081/clt-120019128. J Toxicol Clin Toxicol. 2003. PMID: 12733850 Clinical Trial.
-
Sodium oxybate: a review of its use in the management of narcolepsy.CNS Drugs. 2007;21(4):337-54. doi: 10.2165/00023210-200721040-00007. CNS Drugs. 2007. PMID: 17381187 Review.
-
Sodium oxybate: efficacy, safety and tolerability in the treatment of narcolepsy with or without cataplexy.Drugs Today (Barc). 2008 Mar;44(3):197-204. doi: 10.1358/dot.2008.44.3.1162240. Drugs Today (Barc). 2008. PMID: 18536781 Review.
-
Time to response with sodium oxybate for the treatment of excessive daytime sleepiness and cataplexy in patients with narcolepsy.J Clin Sleep Med. 2015 Apr 15;11(4):427-32. doi: 10.5664/jcsm.4598. J Clin Sleep Med. 2015. PMID: 25580605 Free PMC article. Clinical Trial.
Cited by
-
Pitolisant: A Review in Narcolepsy with or without Cataplexy.CNS Drugs. 2020 Feb;34(2):207-218. doi: 10.1007/s40263-020-00703-x. CNS Drugs. 2020. PMID: 31997137 Review.
-
Healthcare Burden and Productivity Loss Due to Narcolepsy in Sweden.Clocks Sleep. 2025 Feb 19;7(1):8. doi: 10.3390/clockssleep7010008. Clocks Sleep. 2025. PMID: 39982315 Free PMC article.
-
Current Insights on the Impact of Gamma-Hydroxybutyrate (GHB) Abuse.Subst Abuse Rehabil. 2022 Feb 9;13:13-23. doi: 10.2147/SAR.S315720. eCollection 2022. Subst Abuse Rehabil. 2022. PMID: 35173515 Free PMC article. Review.
-
Alcohol withdrawal syndrome: mechanisms, manifestations, and management.Acta Neurol Scand. 2017 Jan;135(1):4-16. doi: 10.1111/ane.12671. Epub 2016 Sep 1. Acta Neurol Scand. 2017. PMID: 27586815 Free PMC article. Review.
-
Analysis of Factors Associated with Hiccups Using the FAERS Database.Pharmaceuticals (Basel). 2021 Dec 24;15(1):27. doi: 10.3390/ph15010027. Pharmaceuticals (Basel). 2021. PMID: 35056084 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical